Nonsteroidal anti-inflammatory drug

United States Pet Medication Market Insights Report 2024-2029 Featuring Prominent Vendors - Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck, Zoetis, Bayer AG, and Novartis - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 17, 2024
Pharmaceutical, Health, Veterinary, USD, Vaccination, Inflammation, Bayer, Nonsteroidal anti-inflammatory drug, Boehringer Ingelheim, Pet, Parasitism, Animal, Insurance, Zoonosis, Urbanization, Tick, Prescription, Cat, Human, Novartis, Family, Pain management, Food, Anesthetic, Dog, Merck, Growth, Prevalence, Medical imaging

The U.S. pet medication market report contains exclusive data on 39 vendors.

Key Points: 
  • The U.S. pet medication market report contains exclusive data on 39 vendors.
  • The competition in the U.S. pet medication market is intense, with several global players offering diverse products.
  • Currently, Ceva, Zoetis, Boehringer Ingelheim, Merck, Elanco, Bayer AG, and Novartis are the leading vendors in pet medication production and distribution in the U.S.
  • The prescription medications segment occupies a significant market share of over 53% in the U.S. pet medication market.

Rakuten Medical's Poster Presentation at AACR 2024 Demonstrates Reduction in Photoimmunotherapy-induced Edema in Mice with COX-2 Inhibition

Retrieved on: 
星期五, 四月 12, 2024
Ephrin A2, Mouse, Nonsteroidal anti-inflammatory drug, Necrosis, Blood, Poster, Thromboxane A2, Research, Edema, Neutrophil, Light, Patient, Neoplasm, Head, AACR, Meloxicam, SAN, Vaccine

In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.

Key Points: 
  • In the study presented in this poster, Rakuten Medical developed a mouse tumor model to assess edema following photoimmunotherapy and evaluated various steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) for edema reduction using the model.
  • It was also confirmed that the reduction in edema with meloxicam was not associated with a loss of therapeutic benefit based on measurement of tumor growth.
  • Control mice did not generate edema, but mice treated with conjugate plus light showed a light-dose dependent increase in edema volume which peaked at 6h post light delivery.
  • The reduction in edema with meloxicam did not have negative impact on tumor growth inhibition.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Retrieved on: 
星期五, 三月 29, 2024
Diagnosis, B cell, Regeneration, TELO, Disease, Research, Nonsteroidal anti-inflammatory drug, MD, Quality of life, Human, Osteoarthritis, FDA, Ageing

BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.

Key Points: 
  • The study will evaluate the efficacy of Telomir-1 for mitigating the progression of osteoarthritis based on symptomatic, radiographic, gross pathologic and histopathologic evaluations.
  • In addition, Telomir believes that this study could be used as part of its pre-clinicial program for eventually evaluating Telomir-1 in humans.
  • It is estimated that nearly 18 million canines in the United States are affected by osteoarthritis.
  • “Osteoarthritis is the most common ailment in canines yet there are currently no treatments that combat the disease.

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Retrieved on: 
星期一, 三月 25, 2024
Prevalence, Exercise, Gastrointestinal bleeding, Risk, GI, Sale, Nonsteroidal anti-inflammatory drug, Running, Veterinary medicine, Motion, OA, Chronic pain, Quality of life, Osteoarthritis, Arthritis, Dog, PROM, Aspirin, Cartilage, Bioelectronics, FDA, Animal, BIEL, Ibuprofen, Audit

Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.

Key Points: 
  • The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
    A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint.
  • BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine.
  • Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in

Retrieved on: 
星期一, 三月 18, 2024
Neurology, Headache, NDS, Patient, Contraindication, Nonsteroidal anti-inflammatory drug, Chronic pain, Migraine, Health Canada, Chemical patent, PALO, OPML, Patent, Therapy, FDA

ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3

Key Points: 
  • ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3
    The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

EMUAID® Unveils Breakthrough Natural Pain Relief Cream, Now Available at Walgreens Nationwide

Retrieved on: 
星期二, 三月 26, 2024
Cream, Arthralgia, Allantoin, First aid, Nonsteroidal anti-inflammatory drug, Arthritis, Arnica, Myalgia, Pain management, Pain, Steroid, Emu oil, Diabetic neuropathy, Cosmetics

This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.

Key Points: 
  • This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.
  • EMUAID® announces the launch of its innovative Pain Relief Cream in Walgreens stores across the United States.
  • The availability of EMUAID®'s Pain Relief Cream in the First Aid section at Walgreens strengthens the brand's accessibility, making it easier for consumers to experience the benefits of natural pain relief.
  • EMUAID® Pain Relief Cream is now available in the First Aid Section at Walgreens stores nationwide.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
星期二, 三月 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
星期二, 三月 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

New Practice Guideline Co-Led by Penn Dental Medicine Details Dental Pain Management Strategies

Retrieved on: 
星期三, 三月 13, 2024
Dental care, JADA, Dentistry, Associate, Patient, Naproxen, Nonsteroidal anti-inflammatory drug, University, Paracetamol, American Dental Association, Wilfrid Sellars, Prescription, Risk, Toothache, Analgesic, Pain, Ibuprofen, Guideline

PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.

Key Points: 
  • PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.
  • The guideline was developed by Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) , the American Dental Association (ADA), and the University of Pittsburgh School of Dental Medicine.
  • Dr. Alonso Carrasco-Labra, Associate Professor and Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine, and Olivia Urquhart, an epidemiologist and instructor within CIGOH, co-led its development.
  • This is the second of two guidelines on acute dental pain management from this research team.